Adze-1.17.FA.4

Adze-1.17.FA.4 is a code-named investigational drug developed by Adze Biotechnology, Inc., as part of its Adze-1.17 oncolytic immunotherapy platform. This platform utilizes a chimeric adenoviral backbone engineered for systemic delivery, designed to evade the liver and restrict replication specifically to cancer cells. The drug is intended to deliver immune-stimulatory transgenes and checkpoint inhibitors, aiming to achieve direct tumor cell killing, release tumor-derived antigens, and modulate the tumor microenvironment to promote a robust and systemic anti-tumor immune response. While specific details for the "FA.4" variant are not available, the platform's overall mechanism involves both local oncolysis and systemic immune activation for the treatment of various solid tumors.